MedTrace Logo

Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT01957956 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-11-18

No results posted yet for this study

Summary

This pilot clinical trial studies vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vaccine therapy and temozolomide may be an effective treatment for glioblastoma.

Conditions

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine

Given ID

DRUG

Temozolomide

Given PO

Sponsors & Collaborators

Principal Investigators

  • Ian Parney · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-11
Primary Completion
2016-11-16
Completion
2016-11-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01957956 on ClinicalTrials.gov